Previous 10 | Next 10 |
2024-05-21 09:21:57 ET More on Eli Lilly, Novo Nordisk Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety The FTC Cracks Down On Novo Nordisk's Ozempic Eli Lilly inks radiopharma deal wort...
2024-05-21 06:43:02 ET Eli Lilly ( NYSE: LLY ) has secured China approval for its blockbuster drug tirzepatide for use in treating diabetes.... Read the full article on Seeking Alpha For further details see: Eli Lilly’s tirzepatide cleared for diabetes treatme...
2024-05-20 12:05:46 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Hims & Hers surges on cheap compounded versio...
2024-05-20 10:15:35 ET More on Hims & Hers Health 10 Solid Reasons To Buy Hims & Hers Stock Hims & Hers: Strong Operating Leverage And Profitability Inflection Hims & Hers: The Growth Story, Coupled With Expanding Profitability, Promises Exponential G...
2024-05-20 10:11:34 ET More on Hims & Hers Health 10 Solid Reasons To Buy Hims & Hers Stock Hims & Hers: Strong Operating Leverage And Profitability Inflection Hims & Hers: The Growth Story, Coupled With Expanding Profitability, Promises Exponential G...
2024-05-20 08:20:00 ET Summary The mean weight loss in a Phase 1b trial of the GLP/GIP against CT-388 (once-a-week injection for 24 weeks) has just read out at 18.8%, with (apparently) no safety signals. Amgen sort-of-announced positive results on its candidate, MariTide. Boeh...
2024-05-19 15:05:03 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety The FTC Cracks Down On Novo Nordisk's Ozempic Biopharma M&A surges year ...
2024-05-19 14:00:55 ET More on pharma companies Novo Nordisk, J&J lead R&D rankings in big pharma: report Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors Johnson & Johnson: Buy This Bargain Before It's Gone ...
2024-05-18 14:52:07 ET More on GSK, Johnson & Johnson, etc. Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors Merck & Co., Inc. (MRK) BofA Securities 2024 Health Care Conference (Transcript) Johnson & Johnson (JNJ) ...
2024-05-18 11:18:53 ET Summary Roche's obesity candidate CT-388 showed positive results in a phase 1b trial, with an 18.8% placebo-adjusted weight loss at week 24. The full data presentation is needed to assess safety and tolerability and how CT-388 stacks up against key competito...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...